Health. Hope. Human.

Gennecs Pharmaceuticals

Gennecs is the pharmaceutical arm of El Daba Holding — a globally recognized, rapidly growing conglomerate based in Egypt, driving growth and innovation across the pharmaceutical sector.

Building a Legacy of Trust & Innovation

Our Legacy

Since 2020, Gennecs has grown into a trusted healthcare partner — driven by scientific excellence, strategic collaboration, and a commitment to improving patient outcomes across regional and international markets.

drug
Foundation
svgexport-6
Expansion
noun-antibody-3153015
Innovation
svgexport-6-1
Manufacturing Excellence
partnerships
Global Partnerships

Pipeline Therapy areas

Building Tomorrow’s Healthcare Solutions

Our pipeline focuses on future healthcare initiatives and innovation-driven advancements to maximize opportunities that will shape a healthier tomorrow.

Diabetes
Oncology
GLP-1 & Peptides
Dietary Supplements
Primary Care
Diabetes
Oncology
GLP-1 & Peptides
Dietary Supplements
Primary Care

Products Portfolio

Oricocoxib
Selective COX-2 inhibitor
Image description
Methorelax
Combination for muscle relaxation
Image description
DasanaJointa
Ultimate ingredient mix for Osteoarthritis patients
Image description
Edocalcium
For Osteoporosis/Osteopenia patients
Image description
GNLI
Anti-infective
Image description

Press Room

People & Development

Adam El Daba Founder & CEO

Gennecs Pharmaceutical / Gennvax

Adam Eldaba is a prominent entrepreneur with extensive experience in establishing, growing, and selling businesses across various sectors. He is the Founder and CEO of Gennecs Pharmaceuticals, the pharmaceutical arm of Eldaba Holding Group, and the main sponsor and investor of Gennvax, the company’s vaccine development division.

Nibal Dahaba, General Manager

Gennecs Pharmaceutical / Gennvax

Nibal Dahaba is a dynamic leader with extensive experience in the pharmaceutical industry. As the General Manager of Gennecs Holding/Gennvax, Nibal has continued to demonstrate her passion for making a difference in healthcare.